This study will use the network of international ICUs to collect plasma and epithelial lining fluid (ELF) data from a wide range of ICU patients treated for lung infections.

This project will be highly valuable in describing the population variability in ELF penetration of antimicrobials including meropenem, piperacillin, ceftriaxone, ceftazidime, cefepime, ciprofloxacin, vancomycin and linezolid.

The data for meropenem, piperacillin, benzylpenicillin and ceftriaxone from Project 2a, will be able to be combined to define robust dosing regimens that achieve therapeutic ELF exposures for these agents. For the remaining antimicrobials, we will use this new knowledge of PK variability to describe the attainment of therapeutic target-site concentrations with contemporary dosing.

Project members

Jason Roberts

Professor Jason Roberts

UQ Centre for Clinical Research
NHMRC Leadership Fellow
The University of Queensland
Pharmacist Consultant
Royal Brisbane & Women’s Hospital

Professor Jeffrey Lipman

Critical Care Research, Translation and Training Lead
Emeritus Professor
UQ Centre for Clinical Research

Professor Jan De Waele

European Collaboration Co-Lead
Critical Care Physician
Ghent University Hospital

Professor Jordi Rello

Professor of Medicine
Universitat Autònoma de Barcelona
Chief of the Critical Care Department
Vall d'Hebron University Hospital